Aktualizacja rekomendacji ASCO /CAP z 2018 roku
w sprawie badań statusu receptora HER 2 w raku piersi

Mirosław Śnietura; Anna Kruczak

ISSN: -

Polish Journal of Pathology Supplement

Current supplement Archive Polish Journal of Pathology

2/2021

Send email

Copy url:

Guidelines/recommendations

Aktualizacja rekomendacji ASCO /CAP z 2018 roku w sprawie badań statusu receptora HER 2 w raku piersi

Mirosław Śnietura

¹

,

Anna Kruczak

²

Zakład Patologii Nowotworów, Narodowy Instytut Onkologii – Państwowy Instytut Badawczy im. Marii Skłodowskiej-Curie, Oddział w Gliwicach
Zakład Patomorfologii Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy, Oddział w Krakowie

Online publish date: 2023/02/02

Article file

- SPJP-supl-1.pdf [0.16 MB]

Get citation

1. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.

2. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

3. J Clin Oncol 2013; 31: 3997-4013.

4. American Society of Clinical Oncology; College of American Pathologists. ASCO/CAP Guidelines: Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology /College of American Pathologists Clinical Practice Guideline Update – Data supplement. Pobrane 7.11.2014 z http://www.asco.org/sites/www.asco.org/files/her2_testing_ds_10-28-14.pdf.

5. Rakha EA, Pigera M, Shaaban A, et al. National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer. J Clin Oncol 2015; 33: 1301-1302

6. Wolff AC, Hammond ME, Hicks DG, et al. Reply to A.E. Rakha et al. J Clin Oncol 2015; 33: 1302-1304

7. Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

8. J Clin Oncol 2018; 36: 2105-2122.

9. College of American Pathologists. ASCO/CAP Guidelines: HER2 Testing in Breast Cancer - 2018 Focused Update. Pobrane 03.01.2022 z https://www.cap.org/protocols-and- guidelines/cap-guidelines/current-cap-guidelines/recommendations-for-human-epidermal-growth-factor-2-testing-in-breast-cancer.

10. Śnietura M, Lange D Aktualne rekomendacje ASCO/CAP 2013 dotyczące badań statusu receptora HER2 w raku piersi. Pol J Pathol 2014; 65 Suppl: S32-S41.

Copyright: © 2023 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Aktualizacja rekomendacji ASCO /CAP z 2018 roku w sprawie badań statusu receptora HER 2 w raku piersi

Mirosław Śnietura 1 , Anna Kruczak 2

Mirosław Śnietura

¹

,

Anna Kruczak

²